Glioblastoma, the Neurosurgeon, and Neuro-Palliative Care
DOI:
https://doi.org/10.17140/PMHCOJ-2-110Keywords:
Neurosurgery, Glioblastoma, Brain tumor, Palliative care, Neuro-palliative careAbstract
Primary malignant brain tumors, such as Glioblastoma multiforme (GBM), carry a poor survival prognosis and lead to a high burden of symptoms for the patient and his/her fam-ily. While advances in treatment modalities have led to increased survival rates for patients with GBM it remains a terminal diagnosis. Recent data has demonstrated that patients who receive early palliative care in addition to standard oncological therapies for non-neural cancers have a better quality of life, receive fewer aggressive treatments, and live significantly longer than those who do not receive early palliative care. To date, palliative care has arguably been an underutilized approach to assist in the management of GBM patients. Patients living with brain tumors have symptoms that differ from patients suffering with non-neural cancers, which raises the future possibility of physicians that are dedicated to palliative management of patients with neurological conditions, such as GBM. Common symptoms for patients actively dying with GBM include headaches, seizures, somnolence and fatigue, dysphagia, focal neurological deficits, and cognitive deficits. Neurosurgeons often have early contact with newly diagnosed brain tumor patients. Therefore, it is of utmost importance for the neurosurgeon to have an appreciation of palliative care for this specific patient population and to also have an understanding of the full spectrum of care that these patients will encounter while living, and dying due to GBM. The purpose of this paper is to review the existing literature surrounding palliative care for patients with malignant brain tumors particularly from the perspective of the neurosurgeon and because of the unique symptoms faced by this patient population introduce the concept of neuro-palliative care.
References
Kross EK, Engelberg RA, Downey L, et al. Differences in end-of-life care in the ICU across patients cared for by medicine, surgery, neurology, and neurosurgery physicians. Chest. 2014; 145(2): 313-321. doi: 10.1378/chest.13-1351
Macdonald RL. When you are old. Stroke. 2014; 45(9): 2830- 2832. doi: 10.1161/STROKEAHA.114.006666
Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352(10): 987-996. doi: 10.1056/NEJ-Moa043330
Tran B, Rosenthal MA. Survival comparison between glio-blastoma multiforme and other incurable cancers. J Clin Neuro-sci. 2010; 17(4): 417-421. doi: 10.1016/j.jocn.2009.09.004
Adamson C, Kanu OO, Mehta AI, et al. Glioblastoma multi-forme: A review of where we have been and where we are go-ing. Expert Opin Investig Drugs. 2009; 18(8): 1061-1083. doi: 10.1517/13543780903052764
Weller M, Stupp R, Reifenberger G, et al. MGMT promoter methylation in malignant gliomas: Ready for personalized medi-cine?. Nat Rev Neurol. 2010; 6(1): 39-51. doi: 10.1038/nrneu-rol.2009.197
Palanichamy K, Chakravarti A. Combining drugs and ra-diotherapy: From the bench to the bedside. Curr Opin Neurol. 2009; 22(6): 625-632. doi: 10.1097/WCO.0b013e3283327d33
Laperriere N, Zuraw L, Cairncross G. Cancer Care Ontario Practice Guidelines Initiative Neuro-Oncology Disease Site Group. Radiotherapy for newly diagnosed malignant glioma in adults: A systematic review. Radiother Oncol. 2002; 64(3): 259- 273. doi: 10.1016/S0167-8140(02)00078-6
Walker MD, Green SB, Byar DP, et al. Randomized com-parisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med. 1980; 303(23): 1323-1329. doi: 10.1056/NEJM198012043032303
Stewart LA. Chemotherapy in adult high-grade glioma: A systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet. 2002; 359(9311): 1011-1018. doi: 10.1016/S0140-6736(02)08091-1
Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiother-apy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009; 10(5): 459-466. doi: 10.1016/S1470-2045(09)70025-7
Karabatsou K, Bernstein M. Cure following gene therapy for recurrent glioblastoma multiforme? Acta Neurochir (Wien). 2008; 150(6): 611-612.
Dehdashti AR, Sharma S, Laperriere N, Bernstein M. Co-incidence vs cause: Cure in three glioblastoma patients treated with brachytherapy. Can J Neurol Sci. 2007; 34(3): 339-342.
Lin E, Rosenthal MA, Le BH, Eastman P. Neuro-oncology and palliative care: A challenging interface. Neuro Oncol. 2012; 14 (Suppl 4): 43-47. doi: 10.1093/neuonc/nos209
Loscalzo MJ. Palliative care: An historical perspective. Hematology Am Soc Hematol Educ Program. 2008, 465. doi: 10.1182/asheducation-2008.1.465
Clark D. From margins to centre: A review of the history of palliative care in cancer. Lancet Oncol. 2007; 8(5): 430-438. doi: 10.1016/S1470-2045(07)70138-9
Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. 2010; 363(8): 733-742. doi: 10.1056/NEJMoa1000678
Heimans JJ, Taphoorn MJ. Impact of brain tumour treatment on quality of life. J Neurol. 2002; 249(8): 955-960.
Walbert T. Integration of palliative care into the neuro-on-cology practice: Patterns in the united states. Neurooncol Pract. 2014; 1(1): 3-7. doi: 10.1093/nop/npt004
Mummudi N, Jalali R. Palliative care and quality of life in neuro-oncology. F1000Prime Rep. 2014; 6: 71-71. doi: 10.12703/P6-71
Walbert T, Khan M. End-of-life symptoms and care in pa-tients with primary malignant brain tumors: A systematic litera-ture review. J Neurooncol. 2014; 117(2): 217-224. doi: 10.1007/ s11060-014-1393-6
Heese O, Vogeler E, Martens T, et al. End-of-life caregivers’ perception of medical and psychological support during the final weeks of glioma patients: A questionnaire-based survey. Neuro Oncol. 2013; 15(9): 1251-1256. doi: 10.1093/neuonc/nos209
Pace A, Di Lorenzo C, Guariglia L, Jandolo B, Carapella CM, Pompili A. End of life issues in brain tumor patients. J Neu-rooncol. 2009; 91(1): 39-43. doi: 10.1007/s11060-008-9670-x
Sizoo EM, Braam L, Postma TJ, et al. Symptoms and prob-lems in the end-of-life phase of high-grade glioma patients. Neuro Oncol. 2010; 12(11): 1162-1166. doi: 10.1007/s00520- 013-2088-9
Pace A, Di Lorenzo C, Capon A, et al. Quality of care and rehospitalization rate in the last stage of disease in brain tumor patients assisted at home: A cost effectiveness study. J Palliat Med. 2012; 15(2): 225-227. doi: 10.1089/jpm.2011.0306
Sizoo EM, Pasman HR, Buttolo J, et al. Decision-making in the end-of-life phase of high-grade glioma patients. Eur J Can-cer. 2012; 48(2): 226-232. doi: 10.1016/j.ejca.2011.11.010
Sizoo EM, Grisold W, Taphoorn MJ. Neurologic aspects of palliative care: The end of life setting. Handb Clin Neurol. 2014; 121: 1219-1225. doi: 10.1016/B978-0-7020-4088-7.00081-X
Pompili A, Telera S, Villani V, Pace A. Home palliative care and end of life issues in glioblastoma multiforme: Results and comments from a homogeneous cohort of patients. Neurosurg Focus. 2014; 37(6): E5. doi: 10.3171/2014.9.FOCUS14493
Budrukkar A, Jalali R, Dutta D, et al. Prospective assessment of quality of life in adult patients with primary brain tumors in routine neurooncology practice. J Neurooncol. 2009; 95(3): 413-419. doi: 10.1007/s11060-009-9939-8
Klein M, Taphoorn MJ, Heimans JJ, et al. Neurobehavioral status and health-related quality of life in newly diagnosed high-grade glioma patients. J Clin Oncol. 2001; 19(20): 4037-4047.
Klein M, Heimans JJ, Aaronson NK, et al. Effect of ra-diotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low-grade gliomas: A compara-tive study. Lancet. 2002; 360(9343): 1361-1368. doi: 10.1016/ S0140-6736(02)11398-5
Crossen JR, Garwood D, Glatstein E, Neuwelt EA. Neurobe-havioral sequelae of cranial irradiation in adults: A review of radiation-induced encephalopathy. J Clin Oncol. 1994; 12(3): 627-642.
Swennen MH, Bromberg JE, Witkamp TD, Terhaard CH, Postma TJ, Taphoorn MJ. Delayed radiation toxicity after focal or whole brain radiotherapy for low-grade glioma. J Neuroon-col. 2004; 66(3): 333-339.
Lipsman N, Skanda A, Kimmelman J, Bernstein M. The atti-tudes of brain cancer patients and their caregivers towards death and dying: A qualitative study. BMC Palliat Care. 2007; 6: 7. doi: 10.1186/1472-684X-6-7
Chastek B, Harley C, Kallich J, Newcomer L, Paoli CJ, Te-itelbaum AH. Health care costs for patients with cancer at the end of life. J Oncol Pract. 2012; 8(6): 75s-80s. doi: 10.1200/ JOP.2011.000469
Langton JM, Blanch B, Drew AK, Haas M, Ingham JM, Pearson SA. Retrospective studies of end-of-life resource utili-zation and costs in cancer care using health administrative data: A systematic review. Palliat Med. 2014; 28(10): 1167-1196. doi: 10.1177/0269216314533813
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Palliative Medicine and Hospice Care (PMHC) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.
